Kneu Health appoints Dr James Goldenberg as U.S. Strategic Clinical Advisor to support growth across health systems

• Dr James Goldenberg, MD, FAAN, a neurologist with more than 30 years in clinical practice, research and physician leadership, joins Kneu Health as U.S. Strategic Clinical Advisor

• Dr Goldenberg is a former American Academy of Neurology board member and helped lead a national neurology practice platform, NIRA Medical

• Dr Goldenberg’s appointment strengthens Kneu Health’s clinical voice in the U.S. as it expands work with health systems and community practices

NEW YORK, November 5, 2026 – Kneu Health, a neurology platform for Parkinson’s disease and dementia, today announced the appointment of James Goldenberg, MD, FAAN as US. Strategic Clinical Advisor. Dr Goldenberg will advise Kneu Health on its U.S. growth strategy and its engagement with neurologists across academic medical centers, community practices and health systems.

Dr Goldenberg practiced neurology in Palm Beach County, Florida, for more than 25 years, with a focus on memory disorders. He served on the Board of Directors of the American Academy of Neurology from 2017 to 2023 and is a Fellow of the Academy. He helped lead NIRA Medical, a national neurology practice platform, serving as Chief Strategy Officer, and was previously Chief Medical Officer of Headlands Research, a multinational clinical trial network. He also founded JEM Research Institute, leading Phase I to IV trials across neurology and psychiatry, and was Medical Director of a clinically integrated network of more than 1,750 physicians. He is an Affiliated Assistant Professor of Neurology at the University of Miami Miller School of Medicine.

The appointment comes as Kneu Health builds on its U.S. momentum. Having achieved FDA 510(k) clearance for smartphone and Apple Watch measurement of Parkinson’s tremor, and launched at Cedars-Sinai and Mass General Brigham, Kneu Health is extending its reach to the wider U.S. neurology community. Dr Goldenberg’s experience across clinical practice, research and physician leadership will help shape how Kneu Health’s platform fits into the day-to-day work of neurology teams.

“Jim brings a wealth of experience as a clinician, health system leader and researcher, alongside a deep understanding of how real-world data can transform neurological care. His insight into clinical practice and the economics of care will be invaluable as we combine continuous, multimodal data with clinical support to help neurology teams reach more patients and deliver more timely, personalized care across the U.S.”

Caroline Cake, CEO and Co-Founder of Kneu Health

“I’m excited to join Kneu Health as an advisor at a time when the opportunity to transform neurological care has never been greater. Kneu’s ability to turn everyday patient interactions into meaningful, continuous clinical insights represents a significant step forward—enabling earlier intervention, more personalized care, and better outcomes for patients and families.”

Dr James Goldenberg

About Kneu Health

Kneu Health is pioneering continuous intelligence for neurological care through monitoring of Parkinson's and dementia. Built on Oxford University's longitudinal research and validated across leading health systems, the company's FDA-cleared platform transforms daily interactions into clinical insights that enable earlier intervention and personalized care. Backed by Oxford Science Enterprises, Cedars-Sinai, and a global syndicate of investors, Kneu operates across ten NHS Trusts and flagship U.S. health systems. Learn more at kneu.com.

Media contact: media@kneu.com